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Abstract
Temozolomide (TMZ) is an oral alkylating agent that is considered the standard therapy in 
primary intracranial malignancies. The medication is well tolerated with a most common side 
effect of bone marrow suppression that is encountered in a small proportion of patients, of-
ten reversible with medication discontinuation and supportive treatment. Rarely, aplastic ane-
mia can develop during treatment with TMZ. Here, we present a case of a patient who devel-
oped aplastic anemia following treatment with TMZ. We offer a review of the existing literature 
to have a better understanding of the causative effect and to examine the characteristics and 
outcomes when aplastic anemia develops during treatment with TMZ.
© 2020 The Author(s).
Published by S. Karger AG, Basel
Introduction
Aplastic anemia (AA) involves the replacement of hematopoietic stem cells in a normal 
bone marrow with fatty infiltrate due to a decrease or abscence of hematopoietic precursors, 
which leads to pancytopenia.
AA can be either genetic or acquired. Acquired AA is further distinguished based on its 
pathophysiology which can be secondary to bone marrow toxicity with a resultant damage of 
hematopoietic stem cells due to the reactive oxygen species (ROS) and mostly is iatrogenic 
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(caused by chemical agents or radiation). The other pathophysiology that accounts for AA is 
autoimmune mediated which involves deregulated T-cells that can result in the destruction 
of hematopoietic stem cell precursors. Alkylating agents used in various solid and hemato-
logic malignancies are notorious for causing bone marrow suppression which is usually tran-
sient and reversible with medication discontinuation and supportive therapy. However, these 
agents have been described to cause AA which manifests by severe and permanent bone 
marrow suppression. One of these alkylating agents, temozolomide (TMZ), has gained its 
wide recognition in the  field of oncology for the treatment of primary intracranial malig-
nancies. The clinical trials that proved the efficacy of TMZ in intracranial tumors demon-
strated mild to moderate suppression of bone marrow with conventional doses, which is 
transient and tolerable in most of the cases. However, there has been anecdotal reports 
describing the development of severe AA during treatment with TMZ. Although rare, this 
complication  poses a challenge for both the physician and the patient, and can negatively 
impact treatment course and outcome.
Case Presentation
A 44-year-old Caucasian female presented to the emergency department due to new 
onset of intermittent headache and progressive memory loss. Her past medical history was 
significant for hypothyroidism and recent electroconvulsive therapy due to major depressive 
disorder. Initial magnetic resonance imaging (MRI) of the brain demonstrated a 3.7 × 2.9 × 
2.7 cm enhancing lesion in the right temporal lobe with surrounding vasogenic edema (Fig. 1). 
The patient underwent craniotomy with gross total resection of the right temporal mass. 
Histopathology revealed a World Health Organization (WHO) Grade III anaplastic astro-
cytoma. Immunohistochemical stain for mutant IDH-1 (p.R132H) was diffusely positive as 
well as widespread loss of ATRX, strong p53 reactivity, and Ki-67 of 50%. Fluorescence in-situ 
hybridization showed loss of 19q and polysomy of chromosome 1 (but no evidence of 
co-deletion). O6-methylguanine-DNA methyltransferase (MGMT) status was not performed. 
Fig. 1. a T2 FLAIR axial MRI of the brain showing slightly heterogenous hyperintense mass in the right tem-
poral lobe with surrounding edema (green arrow). b Coronal MRI of the brain showing the lesion in the right 
temporal lobe (red circle) with compressive signs on the lateral ventricle (white arrow).
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Initial complete blood count (CBC) of the patient indicated: hemoglobin (Hgb) 11.9 g/dL 
(normal values 12–15.5 g/dL), white blood count (WBC) 6.9 × 103/μL (normal values 3.8–9.9 
× 103/μL), absolute neutrophils count (ANC) 1.5 × 103/μL , absolute lymphocytes count (ALC) 
1.4 × 103/μL and platelets (PLT) 370 × 103/μL (normal values 150–400 × 103/μL).
The patient’s Karnofsky performance status was 90%. She was started on radiation (total 
dose of 5,940 cGy delivered in 33 fractions) and TMZ at 75 mg/m2. She experienced grade-1 
toxicity of the skin during her radiation and gastritis, treated with topical steroid cream and 
ranitidine, respectively. She was also on levetiracetam 500 mg daily for seizure prophylaxis 
which was discontinued after her third cycle due to low risk for seizure. On completion of 
chemoradiation, the patient was noted to have lymphopenia and thrombocytopenia with ALC 
of 0.2 × 103/μL and PLT of 109 × 103/μL.
Subsequently, the patient received adjuvant TMZ at 150 mg/m2 for a total of 6 cycles 
over a period of 6 months. Atovaquone was started due to a low CD4+ T-cell count and a 
history of allergy to sulfa drugs. Her CBC prior to starting adjuvant TMZ was Hgb 9.3, WBC 
3.2, PLT 248, ANC 2.4, ALC 0.2 (Table 1). At follow-up 1 month after her final cycle, she was 
noted to have neutropenia with WBC of 1, ANC of 0.6, and ALC of 0.1. Other cell counts were 
within her baseline with Hgb of 11.3 and PLT of 134. Follow-up CBC weekly showed a rapid 
decrease in WBC and PLT over a 2-week period to a WBC of 0.6, Hgb of 9.3, and PLT of 11. 
The patient presented to the emergency department 2 weeks later (2 months after her last 
TMZ treatment) with dyspnea, rash, and paronychia and was found to have severe pancyto-
penia. WBC was 0.1, ANC 0, ALC 0, Hgb 7.1, and PLT of 16. This required PLT and red blood 
cell transfusions, and she was started on a 1-week course of cefuroxime and fluconazole due 
to cellulitis. Atovaquone was stopped due to concern for a possible side effect of myelosup-
pression. A bone marrow biopsy was performed which showed a hypocellular bone marrow 
with preserved trilineage cellularity. At that time, she received further work up including 
HIV, HBV, HCV, EBV, CMV, and parvovirus, all of which were negative. B12 was at the lower 
level of normal at 204 pmol/L (normal range 200–900 pmol/L), and she was started on 
supplementation B12 without notable improvement in her pancytopenia. Two months later, 
she developed neutropenic fever and septic shock secondary to a Bartholin gland abscess 
and rectovaginal fistula. Her laboratory findings at that time were significant for WBC 0.00, 
Hgb 7.3, and PLT of 11. A 2 cm left Bartholin abscess was drained, and she was started on 
broad-spectrum antibiotics due to Enterococcus VRE bacteremia. Due to persistent pancyto-
penia, a repeat bone marrow biopsy was performed, which showed pan-hypoplasia with no 
evidence for neoplastic process and was consistent with AA (Fig. 2). She was started on 
granulocyte monocyte-colony stimulating factor and eltrombopag with no appreciable 
improvement in pancytopenia.
Table 1. Complete blood count results during adjuvant temozolomide and at development of aplastic anemia














At diagnosis of 
aplastic anemia
WBC, ×103/μL 3.2 2.4 2.4 3 2.38 2.2 1 0.1
Hgb, g/dL 9.3 9.9 10.2 10.7 10.6 10.7 11.3 7.1
PLT, ×103/μL 248 152 195 144 166 168 134 16
ANC, ×103/μL 2.4 2.2 1.8 2.4 1.8 1.9 0.6 0.0
ALC, × 103/μL 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0
CD4, ×103/μL 79 46 28 29 27 21 43 10
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Given her severe AA, she received cord blood stem cell transplantation along with fluda-
rabine and melphalan conditioning regimen. Unfortunately, she showed little recovery in cell 
count after transplant.
Her hospitalization was complicated by lung abscesses, pyelonephritis and acute hypoxic 
respiratory failure and required transfer to the intensive care unit (ICU).
The patient expired during her ICU stay due to septic shock and complications from 
multiple organ failure.
Discussion
TMZ is a non-specific cell-phase cytotoxic prodrug that is converted spontaneously into 
its active form in the cellular compartment. It acts by methylation of purine bases causing 
DNA breaks and cell death [1].
The medication has become the standard of care in the treatment of primary intracranial 
malignancies including anaplastic astrocytoma and glioblastoma multiforme (GBM) after 
several clinical trials demonstrated improved progression-free survival and overall survival 
[2]. Moreover, TMZ has shown good response rates in other tumors including metastatic 
melanoma, Ewing sarcoma, and T-cell cutaneous lymphomas, which resulted in an increase 
of its use in field of medical oncology [3].
The hematologic bone marrow toxicity of TMZ was observed in the study of Stupp et al. 
[2] which assessed efficacy of concomitant use of radiotherapy and TMZ followed by adjuvant 
TMZ in the treatment of GBM. During this study, nontrivial (grade 3 and 4) hematologic 
toxicity developed only in the group that received chemoradiation therapy, and no significant 
hematologic toxicities were observed in the control comparative arm that received radio-
therapy alone, demonstrating that the suppressive effect on bone marrow was mainly driven 
by TMZ. It can be noted from the previous study that there were more grade 3 and 4 toxicities 
during the course of receiving adjuvant TMZ compared to the course of concurrent chemora-
diation which could be consistent with a cumulative toxic dose effect on the bone marrow. 
Interestingly, there was no documentation of grade-5 hematologic toxicity or AA [2, 4].
Generally, cytotoxic chemotherapies (especially alkylating agents such as cyclophos-
phamide, chloramphenicol, and busulfan) are notoriously known to have the capacity to 
destroy the bone marrow hematopoietic stem cells. Bone marrow hematologic toxicity caused 
by alkylating agents can either occur as an idiosyncratic phenomenon in the case of chloram-
Fig. 2. A bone marrow biopsy 
with H&E stain showing pan-hy-
pocellularity with aplasia, devoid 
of hematopoietic cells can be not-
ed with scattered lymphocytes 
and predominance of adipocytes 
replacing the normal bone mar-
row structure.
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phenicol or following a dose-dependent pattern with a cumulative dose as seen in cyclophos-
phamide, busulfan, and fludarabine [5]. However, this aforementioned insult to the bone 
marrow does not account for a diagnosis of AA which is defined by severe depletion of the 
hematopoietic stem cell reservoir which is often nonreversible [6].
A dose-dependent causality of permanent bone marrow damage cannot be established 
based on the available anecdotal reports in the case of AA development with the use of TMZ. 
Some cases described the occurrence of AA early in the course of treatment (within 4 weeks 
after initiation of TMZ) [7–9], while other reports including ours were not associated with AA 
development until at least after 4 cycles of TMZ [10] (Table 2 provides a list of case reports 
from the literature).
The mostcommon etiology of acquired AA is believed to be autoimmune mediated, as 
supported by the observation of decreased regulatory T-cell populations [11]. However, 
medication-induced AA seems to be related to direct toxicity on bone marrow hematopoietic 
stem cells rather than immune mediated, and there are no original studies examining the 
nature of medication-induced AA in patients treated with alkylating agents including TMZ, 
given the rarity of its occurrence and inability to establish causality.
There is no sex preponderance in acquired AA, and our observation from case reports on AA 
associated with TMZ with the majority of patients being female, could be an incidental finding. 
However, evidence exists regarding female gender being a risk factor for TMZ hematologic 
toxicity, which was shown in a retrospective study by Becker-Schiebe et al. [12] that included 69 
patients who had glioblastoma and were treated with TMZ and radiation. This study established 
female gender as a risk factor that can predict development of TMZ-induced grade-4 hematologic 
toxicity. The other factor that is suggested to predict severe hematologic toxicity due to TMZ is 
the status of MGMT [13]. MGMT is a DNA repair enzyme that has variable expression in different 
tissue cells. The level of expression and functional status of MGMT were found to correlate with 
prognosis and response to treatment with TMZ in patients who have GBM, as TMZ has more 
Table 2. Case reports of aplastic anemia associated with temozolomide







Villano, 2006 [10] 75 mg/m2 concurrent with 
radiotherapy followed by 200 
mg/m2 5 days in a 28-day cycle
After 4 cycles 45/male Phenytoin, 
carbamazepine, 
ranitidine
T-cell depleted allogenic 
stem cell transplantation
Death 7 months 
after HSCT
Oh, 2010 [7] Concurrent TMZ (dose 
unspecified) with radiation
Day 18 of treatment 63/female Ranitidine Filgrastim, erythropoietin, 
transfusion
N/A
Jalali, 2007 [20] 75 mg/m2 concurrent with 
radiotherapy
After finishing concurrent 
chemoradiation
30/female TMP/SMX, phenytoin G-CSF, transfusion Rapid decline and 
death
Morris, 2009 [8] 90 mg/m2 with concurrent 
radiation
Day 24 of treatment 16/female Not mentioned 8/8 HLA matched unrelated 
donor with bone marrow 
transplantation
Doing well 13 
months after 
transplant
Kopecky, 2010 [21] 75 mg/m2 concurrent with 
radiotherapy
Day 23 of concurrent 
chemoradiation
61/female H2 blockers, anti-
epileptic medication
Transfusion Rapid decline and 
death
Comez, 2010 [22] 150 mg/m2 concurrent with 
radiotherapy
After 3 cycles 31/female Phenytoin No treatment Rapid decline and 
death
Hanna, 2018 [23] 75 mg/m2 concurrent with 
radiation
More than 4 weeks of 
treatment (first 
thrombocytopenia and later 
pancytopenia)
36/female Levetiracetam Filgrastim, transfusion N/A
George, 2009 [24] N/A Day 14 of treatment N/A
female
N/A N/A N/A
TMZ, temozolomide; N/A, not available; HSCT, hematopoietic stem cell transplant; G-CSF, granulocyte colony stimulating factor.
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efficacy in patients who have epigenetic silencing of MGMT promotor by methylation or low 
expression of MGMT levels [14, 15]. It is unclear whether MGMT status in intracranial tumors 
correlates with a similar pattern of abnormality in MGMT within the bone marrow cells. However, 
some individuals can have different  MGMT polymorphisms  in the bone marrow with a lower 
expression of MGMT compared to other tissues, which could explain the increased  bone marrow 
supression observed during treatment with TMZ [13]. Another study done at Mayo Clinic 
included 30 cases of bone marrow suppression induced by TMZ found that females were more 
prone to severe bone marrow suppression during treatment [16]. Synergistic medication 
induced bone marrow suppression could be another reason that accounts for the development 
of AA in some patients treated with TMZ. This is of impotance as many patients with intracranial 
tumors treated with TMZ can be taking other medications that have been implicated in AA devel-
opment such as levetiracetam and trimethoprim/ sulfamethoxazole [17].
The evaluation of patients who develop pancytopenia during treatment with TMZ should 
include investigating other potential causes including infections such as EBV and parvovirus, 
as patients with primary intracranial tumors who are on TMZ are immunocompromised and 
are prone to such infections. Medications other than TMZ should also be considered as the 
culprit, including anti-epileptic drugs which are used for seizure prophylaxis following crani-
otomy in glioblastoma as they have been reported to cause AA [17]. Moreover, trimethoprim/
sulphamethoxazole, which is often used in this patient population (given lymphopenia 
induced by TMZ and increased risk of penumocystis pneumonia), has been reported to be 
associated with the development of AA. The definitive diagnosis of AA requires a bone marrow 
biopsy showing pan-hypocellular bone marrow replaced by adipocytes.
TMZ discontinuation and initiation of supportive therapy (including blood product trans-
fusion for patients with severe thrombocytopenia and acute symptomatic anemia) constitute 
the mainstay of treatment. Supportive therapy is utilized as an approach directed toward 
avoiding extensive transfusion due to the risk of allosensitization in patients who are 
considered candidates for future allogenic hematopoietic stem cell transplantation as a defin-
itive treatment for AA. Other treatment options including thrombopoietin mimetics such as 
eltrombopag could be considered as they have shown durable response in restoring trilineage 
bone marrow cells in refractory AA [18].
Granulocyte colony stimulating factor is less effective in AA given the lack of a hemato-
poietic stem cell reservoir in bone marrow. Hematopoietic stem cell transplantation remains 
the definitive treatment with improved survival, but case reports of patients who develop AA 
after treatment with TMZ did not correlate with improved outcome after hematopoietic stem 
cell transplantation. Of note, a single case report demonstrated a good response in a young 
patient (16 years old) who developed AA secondary to TMZ after receiving 8/8 HLA-matched 
unrelated donor bone marrow transplantation [19].
Conclusion
Aplastic anemia (AA) is a rare complication in association with TMZ. It is difficult to 
predict who will develop AA during treatment given the potential side effect of bone marrow 
suppression which is usually transient and reversible. A high index of suspicion is required 
to establish  the diagnosis of AA and to start early intervention in patients who develop 
persistent pancytopenia during treatment with TMZ. Prognosis is guarded when AA develops 
secondary to TMZ as there is no established effective treatments .
Finally, further studies are needed to evaluate the effect of MGMT polymorphisms on 
TMZ-related severe hematologic toxicity to identify patients who could be at risk of devel-
oping AA during treatment with TMZ.
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